DREAMM-8 Study- Blenrep in Myeloma | Paul Richardson, MD

DREAMM-8 Study- Blenrep in Myeloma | Paul Richardson, MD

Is Earlier CAR-T the Key to Longer Myeloma Control? | Samir Parekh, MBB

Is Earlier CAR-T the Key to Longer Myeloma Control? | Samir Parekh, MBB

Relapsed & Refractory Myeloma: What’s Changing and What’s Next Rahul Banerjee, MD, FACP

Relapsed & Refractory Myeloma: What’s Changing and What’s Next Rahul Banerjee, MD, FACP

Revolutionizing Myeloma Treatment: BCMA/CD19 Dual CAR-T Explained | Shambavi Richard, MD

Revolutionizing Myeloma Treatment: BCMA/CD19 Dual CAR-T Explained | Shambavi Richard, MD

STOMP Trial - Selinexor + Mezigdomide + Dex in Relapsed Myeloma | Paul Richardson, MD

STOMP Trial - Selinexor + Mezigdomide + Dex in Relapsed Myeloma | Paul Richardson, MD

LimiTEC: Limited-Duration Teclistamab Results | Beatrice Razzo, MD & Cindy Chmielewski

LimiTEC: Limited-Duration Teclistamab Results | Beatrice Razzo, MD & Cindy Chmielewski

Ibrutinib + Venetoclax (I+V) for CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD, PhD

Ibrutinib + Venetoclax (I+V) for CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD, PhD

Emerging Treatment for CD30-Positive Lymphoma: A Phase 1 Study | Swetha Thiruvengadam, MD

Emerging Treatment for CD30-Positive Lymphoma: A Phase 1 Study | Swetha Thiruvengadam, MD

Late-Breaking Abstracts:Faster In Vivo CAR-T Cells & Earlier Bispecifics | Faith Davies, MD

Late-Breaking Abstracts:Faster In Vivo CAR-T Cells & Earlier Bispecifics | Faith Davies, MD

Belantamab: Lowering Administration Burden for Myeloma Patients | Attaya Suvannasankha, MD

Belantamab: Lowering Administration Burden for Myeloma Patients | Attaya Suvannasankha, MD

Promising Results with Elranatamab + Iberdomide from MagnetisMM-30| Attaya Suvannasankha, MD

Promising Results with Elranatamab + Iberdomide from MagnetisMM-30| Attaya Suvannasankha, MD